Wegovy Approved By FDA For The Treatment Of Adults With Noncirrhotic MASH With Moderate To Advanced Liver Fibrosis

Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Wegovy (semaglutide) injection 2.4 mg, describing the approval as the first and only glucagon-like peptide-1 receptor agonist (GLP-1 RA) FDA-approved to treat adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver, in conjunction with a reduced-calorie diet and increased physical activity. There is an ongoing study to confirm the clinical benefit of Wegovy in adults with MASH, the announcement stated.

MASH represents a significant . . .